CRISPR Therapeutics' (CRSP) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP - Free Report) in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a $65.00 target price on the stock.

A number of other research analysts also recently commented on the stock. Wall Street Zen raised shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. Stifel Nicolaus decreased their price target on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a research note on Thursday, February 13th. Royal Bank of Canada cut their target price on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a research report on Wednesday, February 12th. Truist Financial raised their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Finally, Evercore ISI upgraded shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and raised their price objective for the company from $60.00 to $99.00 in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $71.75.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP traded down $0.67 on Tuesday, hitting $36.86. The company's stock had a trading volume of 1,256,881 shares, compared to its average volume of 1,690,987. The company has a market capitalization of $3.18 billion, a price-to-earnings ratio of -8.43 and a beta of 1.88. CRISPR Therapeutics has a 12-month low of $30.04 and a 12-month high of $67.88. The stock has a 50 day moving average of $37.05 and a 200-day moving average of $41.94.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same period in the previous year, the company posted ($1.43) earnings per share. CRISPR Therapeutics's quarterly revenue was up 71.6% on a year-over-year basis. Sell-side analysts expect that CRISPR Therapeutics will post -5.16 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 9,973 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $423,054.66. Following the sale, the chief executive officer now directly owns 180,890 shares of the company's stock, valued at $7,673,353.80. This represents a 5.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Greene purchased 7,000 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 26th. The stock was bought at an average price of $44.85 per share, with a total value of $313,950.00. Following the completion of the purchase, the director now directly owns 7,000 shares of the company's stock, valued at approximately $313,950. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 14,021 shares of company stock worth $594,771 in the last 90 days. 4.30% of the stock is owned by company insiders.

Institutional Trading of CRISPR Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC boosted its holdings in CRISPR Therapeutics by 13.3% during the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company's stock valued at $345,929,000 after acquiring an additional 1,192,336 shares during the period. Capital International Investors grew its stake in CRISPR Therapeutics by 10.3% during the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company's stock worth $344,145,000 after buying an additional 816,789 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock worth $150,029,000 after purchasing an additional 1,074,238 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in CRISPR Therapeutics by 182.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company's stock worth $66,452,000 after acquiring an additional 1,262,560 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of CRISPR Therapeutics by 1.9% during the first quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company's stock worth $60,223,000 after purchasing an additional 33,711 shares during the period. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.